Esteban C Gabazza Selected Research

Subcutaneous Infusions

8/2015	Amelioration of Atherosclerosis by the New Medicinal Mushroom Grifola gargal Singer.
12/2014	Synergistic effect of bolus exposure to zinc oxide nanoparticles on bleomycin-induced secretion of pro-fibrotic cytokines without lasting fibrotic changes in murine lungs.
10/2004	Decreased expression of aquaporin-5 in bleomycin-induced lung fibrosis in the mouse.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esteban C Gabazza Research Topics

Disease

19	Fibrosis (Cirrhosis) 01/2022 - 03/2002
18	Asthma (Bronchial Asthma) 08/2021 - 03/2004
18	Insulin Resistance 01/2021 - 02/2002
18	Inflammation (Inflammations) 01/2019 - 05/2003
16	Neoplasms (Cancer) 01/2022 - 02/2002
9	Type 2 Diabetes Mellitus (MODY) 01/2017 - 06/2002
8	Disseminated Intravascular Coagulation 11/2015 - 07/2002
7	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 01/2006
7	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 06/2012
6	Lung Neoplasms (Lung Cancer) 07/2021 - 10/2005
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2017
6	Idiopathic Pulmonary Fibrosis 01/2021 - 03/2002
5	Infections 05/2022 - 07/2002
5	Obesity 01/2021 - 02/2002
5	Diabetes Mellitus 01/2021 - 01/2018
5	Pneumonia (Pneumonitis) 01/2020 - 05/2003
5	Respiratory Hypersensitivity 01/2020 - 04/2012
5	Atherosclerosis 10/2017 - 01/2003
4	Acute Lung Injury 01/2022 - 10/2004
4	Psoriasis (Pustulosis Palmaris et Plantaris) 08/2014 - 01/2012
4	Thrombosis (Thrombus) 02/2004 - 02/2002
3	Disease Progression 01/2022 - 06/2002
3	Stomach Neoplasms (Stomach Cancer) 04/2021 - 09/2003
3	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2017
3	Glucose Intolerance 01/2021 - 02/2002
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 07/2003
3	Airway Remodeling 01/2018 - 07/2014
3	Hypersensitivity (Allergy) 01/2017 - 03/2011
3	Carcinoma (Carcinomatosis) 10/2016 - 04/2002
3	Atopic Dermatitis (Atopic Eczema) 03/2015 - 01/2014
3	Chronic Hepatitis C 02/2013 - 05/2003
3	Thrombophilia 08/2009 - 02/2003
3	Lung Injury 12/2007 - 10/2004
3	Hyperinsulinism (Hyperinsulinemia) 11/2004 - 07/2002
2	Cholecystitis 05/2022 - 04/2009
2	Dehydration (Water Stress) 05/2022 - 01/2017
2	Melanoma (Melanoma, Malignant) 01/2022 - 01/2011
2	Hyperglycemia 05/2021 - 08/2017
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 01/2016
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 06/2009
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 11/2020
2	Body Weight (Weight, Body) 01/2021 - 12/2018
2	Adenocarcinoma of Lung 10/2020 - 02/2018
2	Rhinosinusitis 01/2017 - 01/2011

Drug/Important Bio-Agent (IBA)

19	Glucose (Dextrose)FDA LinkGeneric 05/2021 - 02/2002
12	CytokinesIBA 01/2020 - 03/2004
10	ThrombomodulinIBA 01/2021 - 01/2003
9	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 03/2002
8	Insulin (Novolin)FDA Link 01/2021 - 07/2002
8	Dacarbazine (DIC)FDA LinkGeneric 11/2015 - 07/2002
7	Protein CIBA 01/2015 - 01/2003
6	Protein SIBA 06/2021 - 01/2016
6	Immunoglobulin E (IgE)IBA 01/2020 - 03/2004
6	AllergensIBA 01/2020 - 12/2006
6	Proteins (Proteins, Gene)FDA Link 03/2019 - 02/2004
6	OvalbuminIBA 02/2018 - 03/2004
6	AnticoagulantsIBA 10/2017 - 05/2003
6	Thrombin FDA Link 10/2017 - 07/2002
6	Hemostatics (Antihemorrhagics)IBA 02/2015 - 01/2003
6	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 10/2013 - 02/2002
5	Pharmaceutical PreparationsIBA 05/2022 - 01/2011
5	Messenger RNA (mRNA)IBA 07/2020 - 04/2003
5	EnzymesIBA 10/2017 - 02/2002
5	Thromboplastin (Tissue Factor)IBA 01/2006 - 02/2002
4	Tyrosine Kinase InhibitorsIBA 01/2021 - 02/2018
4	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2019 - 01/2018
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2017 - 12/2007
4	CollagenIBA 05/2012 - 04/2006
4	Fibrinogen (Factor I)FDA Link 07/2008 - 01/2003
4	FibrinIBA 04/2006 - 01/2003
3	Monoclonal AntibodiesIBA 01/2022 - 08/2014
3	Peptides (Polypeptides)IBA 01/2022 - 01/2020
3	Blood Glucose (Blood Sugar)IBA 05/2021 - 07/2002
3	fibrin fragment D (D-dimer)IBA 01/2021 - 01/2003
3	Biological ProductsIBA 10/2020 - 05/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2018 - 06/2012
3	InterleukinsIBA 02/2018 - 06/2012
3	Interleukin-10 (Interleukin 10)IBA 02/2018 - 03/2011
3	antithrombin III-protease complexIBA 08/2009 - 01/2003
3	Protein C InhibitorIBA 10/2007 - 02/2004
3	Triglycerides (Triacylglycerol)IBA 02/2004 - 08/2003
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2022 - 09/2003
2	Immune Checkpoint ProteinsIBA 01/2022 - 07/2021
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 12/2006
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 01/2017
2	ErbB Receptors (EGF Receptor)IBA 10/2020 - 08/2018
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2020 - 04/2006
2	LipopolysaccharidesIBA 03/2019 - 01/2003
2	SteroidsIBA 12/2018 - 06/2012
2	Anaplastic Lymphoma KinaseIBA 09/2018 - 09/2017
2	CrizotinibIBA 09/2018 - 01/2017
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2018 - 02/2018
2	osimertinibIBA 08/2018 - 02/2018
2	Matrix Metalloproteinases (MMPs)IBA 01/2018 - 01/2004
2	Ethanol (Ethyl Alcohol)IBA 10/2017 - 01/2011

Therapy/Procedure

34	Therapeutics 05/2022 - 06/2002
6	Aftercare (After-Treatment) 05/2022 - 06/2002
3	Renal Dialysis (Hemodialysis) 01/2021 - 01/2003
3	Subcutaneous Infusions 08/2015 - 10/2004
2	Molecular Targeted Therapy 11/2018 - 01/2015